Effects of @entity2544 infusion on the @entity2124 ( @entity2124 ) and prolactin response to @entity2124 -releasing hormone administration in XXXX .

@entity1 @entity2544 @entity844 @entity7704 @entity2124 @entity2012
Since @entity2544 has been shown to blunt the @entity2124 response to @entity7704 ( @entity7704 ) in normal subjects, we investigated whether the same effect of @entity2544 administration could be reproduced in @entity1 with active @entity2012 . Ten acromegalic @entity1 received on two different days 100 micrograms @entity7704 iv alone and the same @entity7704 dose during a constant infusion of @entity2544 (3.56 mg/min), beginning 2 h before @entity7704 administration. In the whole group @entity2544 did not affect basal @entity2124 secretion significantly (from a mean of 44.6 +/- 14.4 at 0 min to 41.8 +/- 13.5 ng/ml at 120 min). However, the amount of @entity2124 released after @entity7704 stimulation was lower when @entity2544 was concomitantly infused (7525 +/- 3709 ng min/ml vs. 12038 +/- 6337 ng min/ml; p less than 0.05). The inhibitory effect of @entity2544 was not homogeneous, since either marked or minimal reductions of the @entity7704 -stimulated @entity2124 secretion occurred. Serum PRL levels increased after @entity7704 administration in 6 @entity1 and @entity2544 infusion had no influence upon this response. Peak @entity7704 levels were not different in both studies (14.9 +/- 1.7 and 17.1 +/- 4.0 ng/ml, respectively). Free @entity844 levels rose progressively during @entity2544 administration (from 0.66 +/- 0.10 at 0 min to 1.04 +/- 0.10 mEq/l at 240 min) and were significantly higher than after @entity7704 stimulation alone from 180 min up to the end of the test. Our results demonstrate that in active @entity2012 @entity2544 blunts the @entity2124 response to @entity7704 , though this effect is not uniformly seen in all @entity1 .(ABSTRACT TRUNCATED AT 250 WORDS)
